Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
Shire Korea is now moving on without Abbvie
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Dec 19, 2014 08:33:14
Shire Korea, a Korean subsidiary of Shire, will enter Korean pharmaceutical market soon as Abbvie decided not to acquire Shire recently.

Shire’s products have been marketed by Yuhan, JW Choongwae, and SK Chemicals in South Korea. Once Shire Korea is founded, it will be able to market some of its products, including ADHD drugs, by itself.

An official of Shire said, “The process has been delayed due to the M&A issue. Now it is cleared. We are hiring people and moving on to open our branch office in Korea. Currently we are supporting partner companies who sell our products in Korea.”

Shire is a specialty pharmaceutical company that focuses on treatments for rare diseases and ADHD. Shire’s Adderall is one of well-known brand-name drugs for ADHD in U.S.
 
Reply 0
Name Password
Text
 
Popular News
 
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com